CoChat

The Highly Recurrent PP2A Aα-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis

Open access
Taylor, Sarah E., O'Connor, Caitlin M., Wang, Zhizhi, Shen, Guobo, Song, Haichi, Leonard, Daniel, Sangodkar, Jaya, LaVasseur, Corinne, Avril, Stefanie, Waggoner, Steven, Zanotti, Kristine, Armstrong, Amy J., Nagel, Christa, Resnick, Kimberly, Singh, Sareena, Jackson, Mark W., Xu, Wenqing, Haider, Shozeb, DiFeo, Analisa, Narla, Goutham · 2019 · Cancer Research

Published version of a preprint

Cited by 59

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

Somatic mutation of the protein phosphatase 2A (PP2A) Aα-subunit gene PPP2R1A is highly prevalent in high-grade endometrial carcinoma. The structural, molecular, and biological basis by which the most recurrent endometrial carcinoma–specific mutation site P179 facilitates features of endometrial carcinoma malignancy has yet to be fully determined. Here, we used a series of structural, biochemical, and biological approaches to investigate the impact of the P179R missense mutation on PP2A function. Enhanced sampling molecular dynamics simulations showed that arginine-to-proline substitution at the P179 residue changes the protein's stable conformation profile. A crystal structure of the tumor-derived PP2A mutant revealed marked changes in A-subunit conformation. Binding to the PP2A catalytic subunit was significantly impaired, disrupting holoenzyme formation and enzymatic activity. Cancer cells were dependent on PP2A disruption for sustained tumorigenic potential, and restoration of wild-type Aα in a patient-derived P179R-mutant cell line restored enzyme function and significantly attenuated tumorigenesis and metastasis in vivo. Furthermore, small molecule–mediated therapeutic reactivation of PP2A significantly inhibited tumorigenicity in vivo. These outcomes implicate PP2A functional inactivation as a critical component of high-grade endometrial carcinoma disease pathogenesis. Moreover, they highlight PP2A reactivation as a potential therapeutic strategy for patients who harbor P179R PPP2R1A mutations. Significance: This study characterizes a highly recurrent, disease-specific PP2A PPP2R1A mutation as a driver of endometrial carcinoma and a target for novel therapeutic development. See related commentary by Haines and Huang, p. 4009

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-19-0218

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 20 references

Research works printed but not linked: 45

  1. Siegel, 2018, Cancer statistics, 2018, CA Cancer J Clin, 68, 7, 10.3322/caac.21442 · DOI · Paper page
  2. Hamilton, 2006, Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers, Br J Cancer, 94, 642, 10.1038/sj.bjc.6603012 · DOI · Paper page
  3. Remmerie, 2018, Targeted therapies in type II endometrial cancers: too little, but not too late, Int J Mol Sci, 19, 10.3390/ijms19082380 · DOI
  4. Cantrell, 2015, Uterine carcinosarcoma: a review of the literature, Gynecol Oncol, 137, 581, 10.1016/j.ygyno.2015.03.041 · DOI · Paper page
  5. Arend, 2011, Uterine carcinosarcoma, Curr Opin Oncol, 23, 531, 10.1097/CCO.0b013e328349a45b · doi:10.1097/cco.0b013e328349a45b
  6. Felix, 2011, Comparison of survival outcomes between patients with malignant mixed mullerian tumors and high-grade endometrioid, clear cell, and papillary serous endometrial cancers, Int J Gynecol Cancer, 21, 877, 10.1097/IGC.0b013e31821a62dd · DOI
  7. Zhao, 2013, Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma, Proc Natl Acad Sci U S A, 110, 2916, 10.1073/pnas.1222577110 · DOI · Paper page
  8. Cancer Genome Atlas Research Network, 2013, Integrated genomic characterization of endometrial carcinoma, Nature, 497, 67, 10.1038/nature12113 · DOI · Paper page
  9. Gibson, 2016, The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis, Nat Genet, 48, 848, 10.1038/ng.3602 · DOI · Paper page
  10. Cherniack, 2017, Integrated Molecular characterization of uterine carcinosarcoma, Cancer Cell, 31, 411, 10.1016/j.ccell.2017.02.010 · DOI · Paper page
  11. Ruediger, 2001, Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene, Oncogene, 20, 10, 10.1038/sj.onc.1204059 · DOI
  12. Jeong, 2016, Patient derived mutation W257G of PPP2R1A enhances cancer cell migration through SRC-JNK-c-Jun pathway, Sci Rep, 6, 27391, 10.1038/srep27391 · DOI · Paper page
  13. Nagaraj, 2015, Critical role of Wnt/beta-catenin signaling in driving epithelial ovarian cancer platinum resistance, Oncotarget, 6, 23720, 10.18632/oncotarget.4690 · DOI · Paper page
  14. Takahashi, 2011, Development of a mouse model for lymph node metastasis with endometrial cancer, Cancer Sci, 102, 2272, 10.1111/j.1349-7006.2011.02099.x · DOI
  15. Otwinowski, 1997, Processing of X-ray diffraction data collected in oscillation mode, Methods Enzymol, 276, 307, 10.1016/S0076-6879(97)76066-X · DOI · Paper page
  16. McCoy, 2007, Phaser crystallographic software, J Appl Crystallogr, 40, 658, 10.1107/S0021889807021206 · DOI · Paper page
  17. Emsley, 2010, Features and development of Coot, Acta Crystallogr D Biol Crystallogr, 66, 486, 10.1107/S0907444910007493 · DOI · Paper page
  18. CCP4, 1994, The CCP4 suite: programs for protein crystallography, Acta Crystallogr D Biol Crystallogr, 50, 760, 10.1107/S0907444994003112 · DOI · Paper page
  19. Abagyan, 1994, ICM—A new method for protein modeling and design: applications to docking and structure prediction from the distorted native conformation, J Comput Chem, 15, 488, 10.1002/jcc.540150503 · DOI · Paper page
  20. Case, 2005, The Amber biomolecular simulation programs, J Comput Chem, 26, 1668, 10.1002/jcc.20290 · DOI · Paper page
  21. Maier, 2015, ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB, J Chem Theory Comput, 11, 3696, 10.1021/acs.jctc.5b00255 · DOI · Paper page
  22. Price, 2004, A modified TIP3P water potential for simulation with Ewald summation, J Chem Phys, 121, 10096, 10.1063/1.1808117 · DOI · Paper page
  23. Doerr, 2016, HTMD: high-throughput molecular dynamics for molecular discovery, J Chem Theory Comput, 12, 1845, 10.1021/acs.jctc.6b00049 · DOI · Paper page
  24. Harvey, 2009, ACEMD: accelerating biomolecular dynamics in the microsecond time scale, J Chem Theory Comput, 5, 1632, 10.1021/ct9000685 · DOI · Paper page
  25. Bonomi, 2009, Reconstructing the equilibrium Boltzmann distribution from well-tempered metadynamics, J Comput Chem, 30, 1615, 10.1002/jcc.21305 · DOI · Paper page
  26. Skliros, 2012, The importance of slow motions for protein functional loops, Phys Biol, 9, 014001, 10.1088/1478-3975/9/1/014001 · DOI
  27. Hess, 2008, GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation, J Chem Theory Comput, 4, 435, 10.1021/ct700301q · DOI · Paper page
  28. Dolinsky, 2004, PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations, Nucleic Acids Res, 32, W665, 10.1093/nar/gkh381 · DOI · Paper page
  29. Baker, 2001, Electrostatics of nanosystems: application to microtubules and the ribosome, Proc Natl Acad Sci U S A, 98, 10037, 10.1073/pnas.181342398 · DOI · Paper page
  30. McConechy, 2011, Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas, J Pathol, 223, 567, 10.1002/path.2848 · DOI · Paper page
  31. Shih, 2011, Somatic mutations of PPP2R1A in ovarian and uterine carcinomas, Am J Pathol, 178, 1442, 10.1016/j.ajpath.2011.01.009 · DOI
  32. Nagendra, 2012, PPP2R1A mutations are common in the serous type of endometrial cancer, Mol Carcinog, 51, 826, 10.1002/mc.20850 · DOI · Paper page
  33. Morris, 1992, Stereochemical quality of protein structure coordinates, Proteins, 12, 345, 10.1002/prot.340120407 · DOI · Paper page
  34. Velazquez, 2015, Dynamical role of phosphorylation on serine/threonine-proline Pin1 substrates from constant force molecular dynamics simulations, J Chem Phys, 142, 075102, 10.1063/1.4907884 · DOI
  35. Dugave, 2003, Cis-trans isomerization of organic molecules and biomolecules: implications and applications, Chem Rev, 103, 2475, 10.1021/cr0104375 · DOI · Paper page
  36. Lu, 2007, Prolyl cis-trans isomerization as a molecular timer, Nat Chem Biol, 3, 619, 10.1038/nchembio.2007.35 · DOI · Paper page
  37. Wedemeyer, 2002, Proline cis-trans isomerization and protein folding, Biochemistry, 41, 14637, 10.1021/bi020574b · DOI · Paper page
  38. Andreotti, 2003, Native state proline isomerization: an intrinsic molecular switch, Biochemistry, 42, 9515, 10.1021/bi0350710 · DOI · Paper page
  39. Zhang, 2009, PR55 alpha, a regulatory subunit of PP2A, specifically regulates PP2A-mediated beta-catenin dephosphorylation, J Biol Chem, 284, 22649, 10.1074/jbc.M109.013698 · DOI · Paper page
  40. Kastrinsky, 2015, Reengineered tricyclic anti-cancer agents, Bioorg Med Chem, 23, 6528, 10.1016/j.bmc.2015.07.007 · DOI · Paper page
  41. Hahn, 2002, Enumeration of the simian virus 40 early region elements necessary for human cell transformation, Mol Cell Biol, 22, 2111, 10.1128/MCB.22.7.2111-2123.2002 · DOI · Paper page
  42. Strack, 2004, Critical role for protein phosphatase 2A heterotrimers in mammalian cell survival, J Biol Chem, 279, 47732, 10.1074/jbc.M408015200 · DOI · Paper page
  43. Dudley, 2016, Microsatellite instability as a biomarker for PD-1 blockade, Clin Cancer Res, 22, 813, 10.1158/1078-0432.CCR-15-1678 · DOI · Paper page
  44. Gao, 2013, Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Sci Signal, 6, pl1, 10.1126/scisignal.2004088 · DOI · Paper page
  45. Cerami, 2012, The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data, Cancer Discov, 2, 401, 10.1158/2159-8290.CD-12-0095 · DOI · Paper page

Cited by

See all 59

Metadata

Authors
Taylor, S. E., O'Connor, C. M., Wang, Z., Shen, G., Song, H., Leonard, D., Sangodkar, J., LaVasseur, C., Avril, S., Waggoner, S., Zanotti, K., Armstrong, A. J., Nagel, C., Resnick, K., Singh, S., Jackson, M. W., Xu, W., Haider, S., DiFeo, A., & Narla, G.
Venue
Cancer Research
Published
2019-08-15
Volume
79
Issue
16
Pages
4242-4257
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2947070173
Cited by
59
References
20
FWCI
1.72
Type
journal article
Language
en
Open access
green
Funders
  • NIH NCI (R01 CA181654, R01 CA197780, F30 CA224979)
  • Department of Defense (OC150553)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Highly Recurrent PP2A Aα-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis. https://app.cochat.ai/papers/10.1158/0008-5472.can-19-0218
The paper
Taylor, S. E., O'Connor, C. M., Wang, Z., Shen, G., Song, H., Leonard, D., Sangodkar, J., LaVasseur, C., Avril, S., Waggoner, S., Zanotti, K., Armstrong, A. J., Nagel, C., Resnick, K., Singh, S., Jackson, M. W., Xu, W., Haider, S., DiFeo, A., & Narla, G. (2019). The Highly Recurrent PP2A Aα-Subunit Mutation P179R Alters Protein Structure and Impairs PP2A Enzyme Function to Promote Endometrial Tumorigenesis. Cancer Research. https://doi.org/10.1158/0008-5472.can-19-0218

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.